KSKatrin Schmidt

Katrin Schmidt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Katrin Schmidt has a total of 176 co-authors. Here are the top co-authors by number of shared publications:

  • Christian von Heymann

    Department of Anaesthesiology and Operative Intensive Care Medicine (CVK), Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany

    2 shared publications
  • Claudia Spies

    Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Anesthesiology and Intensive Care Medicine (CCM | CVK), Augustenburger Platz 1, 13353 Berlin, Germany

    2 shared publications
  • Elisabeth Langer

    Labor Berlin-Charité Vivantes, Charité-Universitätsmedizin Berlin, Campus Charité Mitte, Berlin, Germany

    2 shared publications
  • Adrian Rosada

    1 shared publication
  • Agnieszka Deutschmann

    1 shared publication
  • Alexander Paulus

    1 shared publication

Latest Publications

  • Open Access

    Supervised multimodal prehabilitation of older patients with frailty or prefrailty before elective surgery: a multicentre randomised controlled outcome assessor-blinded trial

    by Claudia Spies, Katrin Schmidt, Jörn Kiselev, Stefan Buchka, Manfred Blobner, Friedrich Borchers, Maria Fabian, Verena Loidl, Ursula Marschall, Rudolf Mörgeli, et al.


  • Reversal of apixaban induced alterations in haemostasis by different coagulation factor concentrates in patients after hip or knee replacement surgery

    by Katrin Schmidt, Kerstin Kruger, Elisabeth Langer, Martin Schmutzler, Elke Johnen, Klaus D. Wernecke, Christian von Heymann, Mareike K. Koerber

    Background. Apixaban is a direct oral anticoagulant (DOAC) with a specific inhibition of activated factor X (FXa). In case of bleeding or need of urgent surgery a direct antidote is not yet available. Off-label application of non-specific haemostatic agents, such as prothrombin complex concentrate (PCC) and recombinant FVIIa (rFVIIa), has been reported to reverse the effects of apixaban in in vitro and animal studies. The aim of this study is to measure the reversal potential of PCC and rFVIIa in patients with prophylactic apixaban concentrations. Material and methods. Whole blood from patients under prophylactic therapy with apixaban was spiked with two doses of PCC or rFVIIa. Thromboelastometry (ROTEM (R)), prothrombin time (PT), and activated partial prothrombin time (aPTT) were performed. Results. Prolongations in PT and aPTT were corrected by the different concentrates with variable efficacies (PCC<rFVIIa) for all time points after medication. Compared with baseline, the reversal effects ranged from partial correction (PCC) to overcorrection of the CT-ExTEM, PT and aPTT by rFVIIa. Discussion. PCC partially reverses the effect of apixaban as measured by point-of-care coagulation testing and standard coagulation tests. Only rFVIIa reliably reverses apixaban anticoagulation.


  • QCM-D surpassing clinical standard for the dose administration of new oral anticoagulant in the patient of coagulation disorders

    by Munawar Hussain, Hans Peter Wendel, Katrin Schmidt, Elisabeth Langer, Mareike Kristina Körber, Oksana Faul, Hinnak Northoff, Christian von Heymann, Frank K. Gehring


  • The Effect of Computerized Tailored Brief Advice on At-risk Drinking in Subcritically Injured Trauma Patients

    by Tim Neumann, Bruno Neuner, Edith Weiss-Gerlach, Hanne Tønnesen, Larry M Gentilello, Klaus-D Wernecke, Katrin Schmidt, Torsten Schröder, Helmar Wauer, Andreas Heinz, et al.

    One-third of injured patients treated in the emergency department (ED) have an alcohol use disorder (AUD). Few are screened and receive counseling because ED staff have little time for additional tasks. We hypothesized that computer technology can screen and provide an intervention that reduces at-risk drinking (British Medical Association criteria) in injured ED patients. In all, 3,026 subcritically injured patients admitted to an ED were screened for an AUD using a laptop computer that administered the AUD Identification Test (AUDIT) and assessed motivation to reduce drinking. Patients with a positive AUDIT (n = 1,139) were randomized to an intervention (n = 563) or control (n = 576) condition. The computer generated a customized printout based on the patient's own alcohol use pattern, level of motivation, and personal factors, which was provided in the form of feedback and advice. Most patients (85%) used the computer with minimal assistance. At study entry, a similar proportion in each group met criteria for at-risk drinking (49.6% versus 46.8%, p = 0.355). At 6 months, 21.7% of intervention and 30.4% of control patients met criteria for at-risk drinking (p = 0.008). Intervention patients also had a 35.7% decrease in alcohol intake, compared with a 20.5% decrease in controls (p = 0.006). At 12 months, alcohol intake decreased by 22.8% in the intervention group versus 10.9% in controls (p = 0.023), but the proportion of at-risk drinkers did not significantly differ (37.3% versus 42.6%, p = 0.168). The computer-generated intervention was associated with a significant decrease in alcohol use and at-risk drinking. Research is needed to further evaluate and adapt information technology to provide preventive clinical services in the ED.